Development of an oral rutin nanocrystal formulation.

Dried rutin nanocrystals have been prepared by lyophilization and investigated regarding their physicochemical properties with respect to re-dispersability, particle size, morphology and dissolution behavior. Photon correlation spectroscopy (PCS) and laser diffractometry (LD) were employed to determine the particle size. Morphology of the particles was analyzed by light microscopy. Lyophilized rutin nanocrystals were incorporated into tablets and the dissolution behavior of the tablets was evaluated. Very fine particles of lyophilized rutin could be completely re-dispersed in the water. The PCS size average and polydispersity index (PI) of lyophilized rutin were of 721nm and of 0.288 after re-dispersion. The rutin nanocrystal-loaded tablets were produced using direct compression. The dissolution velocity of the rutin nanocrystal-loaded tablet was superior compared to rutin microcrystal-loaded and a marketed tablet. After 30min rutin was released and dissolved completely from the nanocrystal tablets in water. In contrast, only 71% and 55% of the total amount of rutin were dissolved from the microcrystal tablets and the marketed tablet, respectively. The improving dissolution behavior of the rutin nanocrystal-loaded tablet should lead to a better bioavailability of the poorly soluble rutin in the body.

[1]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[2]  R. Bye,et al.  Smooth muscle relaxing flavonoids and terpenoids from Conyza filaginoides. , 1997, Planta medica.

[3]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  U. Mohammed,et al.  Naturally occurring polyphenolic antioxidants modulate IgE‐mediated mast cell activation , 2000, Immunology.

[5]  G. Williamson,et al.  Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma , 2001, British Journal of Nutrition.

[6]  Rachmat Mauludin,et al.  Nanosuspensions of poorly soluble drugs for oral administration , 2009 .

[7]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[8]  F. Jung,et al.  Leg oedema protection from a buckwheat herb tea in patients with chronic venous insufficiency: a single-centre, randomised, double-blind, placebo-controlled clinical trial , 1996, European Journal of Clinical Pharmacology.

[9]  Donald L. Wise,et al.  Nanosuspensions: A Formulation Approach for Poorly Soluble and Poorly Bioavailable Drugs , 2000 .

[10]  Helmut Hahn,et al.  Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis , 2001, Antimicrobial Agents and Chemotherapy.

[11]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[12]  G. Liversidge,et al.  Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .

[13]  S. Yamashita,et al.  Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.

[14]  R. H. Müller,et al.  Nanosuspensionen: Formulierungen für schwerlösliche Arzneistoffe mit geringer Bioverfügbarkeit. 2. Mitteilung: Stabilität, biopharmazeutische Aspekte, mögliche Arzneiformen und Zulassungsfragen , 1999 .

[15]  Y. M. Rao,et al.  Formulation of Nanosuspensions of Albendazole for Oral Administration , 2008 .

[16]  Myung‐Sook Choi,et al.  Effect of rutin and tannic acid supplements on cholesterol metabolism in rats , 2002 .

[17]  R. J. Hintz,et al.  The effect of particle size distribution on dissolution rate and oral absorption , 1989 .

[18]  R. Müller,et al.  Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. , 2001, International journal of pharmaceutics.

[19]  Rainer H Müller,et al.  Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  O. Kayser,et al.  DissoCubes‚ÄîA Novel Formulation for Poorly Soluble and Poorly Bioavailable Drugs , 2002 .

[21]  Chun-ching Lin,et al.  Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. , 2008, International journal of pharmaceutics.

[22]  F. Hirayama,et al.  Improvement of Solubility and Oral Bioavailability of Rutin by Complexation with 2-Hydroxypropyl-β-cyclodextrin , 2000, Pharmaceutical development and technology.

[23]  A. Noyes,et al.  The rate of solution of solid substances in their own solutions , 1897 .

[24]  A. Gilani,et al.  Protective effect of rutin on paracetamol- and CCl4-induced hepatotoxicity in rodents. , 2002, Fitoterapia.

[25]  G. Wong,et al.  Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. , 1991, Carcinogenesis.

[26]  M. Luczak,et al.  Influence of flavonoids on combined experimental infections with EMC virus and Staphylococcus aureus in mice. , 1989, Acta microbiologica Polonica.

[27]  A. Beezer,et al.  The relationship between particle size and solubility , 1992 .

[28]  B. Leclerc,et al.  Compaction behaviour and new predictive approach to the compressibility of binary mixtures of pharmaceutical excipients. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[29]  V. Villari,et al.  The rutin/beta-cyclodextrin interactions in fully aqueous solution: spectroscopic studies and biological assays. , 2005, Journal of pharmaceutical and biomedical analysis.

[30]  K. Amighi,et al.  Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. , 2005, International journal of pharmaceutics.

[31]  K. Johnston,et al.  Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs , 2004, Drug development and industrial pharmacy.

[32]  Effect of Explotab on the tabletability of a poorly soluble drug. , 1998, Drug development and industrial pharmacy.

[33]  R. Pardini,et al.  Inhibition of mitochondrial respiration and production of toxic oxygen radicals by flavonoids. A structure-activity study. , 1986, Biochemical pharmacology.

[34]  R. K. Bhattacharya,et al.  Protective effect of rutin, a flavonol glycoside, on the carcinogen-induced DNA damage and repair enzymes in rats. , 1996, Cancer letters.

[35]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.